This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [02.01.2019] – [Aging and Olmesartan] sallieq | home:food:aim_health:aging [07.01.2019] – [Health Maintenance and Olmesartan] sallieq | ||
---|---|---|---|
Line 5: | Line 5: | ||
Summary of research on aging and Olmesartan | Summary of research on aging and Olmesartan | ||
taken from article [[home: | taken from article [[home: | ||
+ | |||
+ | < | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
- | | + | Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent |
- | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | + | |
- | + | ||
- | Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed> | + | |
The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
- | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | + | |
+ | |||
+ | Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. | ||
+ | |||
+ | Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | ||
+ | |||
+ | Administration of olmesartan suppressed the accumulation of macrophages in brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed> | ||
+ | |||
+ | Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat) (({{pubmed> | ||
+ | |||
+ | Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats. (({{pubmed> | ||
+ | |||
+ | Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. (({{pubmed> | ||
+ | |||
+ | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed> | ||
+ | |||
+ | Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
+ | |||
+ | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
- | Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | ||
==== General research on aging ==== | ==== General research on aging ==== | ||
- | When using off-label Olmesartan, patients are observed | + | Holistic vitamin D supplementation with or without calcium is unlikely |
- | These articles | + | When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. |
==== Some of the documented protective effects of ARBs ==== | ==== Some of the documented protective effects of ARBs ==== | ||
| | ||
Line 32: | Line 49: | ||
* inhibit liver fibrosis and aid liver healing(({{pubmed> | * inhibit liver fibrosis and aid liver healing(({{pubmed> | ||
* reduce insulin resistance in rats(({{pubmed> | * reduce insulin resistance in rats(({{pubmed> | ||
- | * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed> | + | |
* protect the mitochondria from age-associated damage from oxidation(({{pubmed> | * protect the mitochondria from age-associated damage from oxidation(({{pubmed> | ||
* play a protective role against proliferative diabetic retinopathy (({{pubmed> | * play a protective role against proliferative diabetic retinopathy (({{pubmed> | ||
Line 83: | Line 100: | ||
=== A number of studies have found === | === A number of studies have found === | ||
- | that olmesartan | + | that olmesartan |
* in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | * in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, | ||
* in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed> | ||
- | * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed> | + | * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis |
- | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> | + | * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed> |
* olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects | ||
- | === Recent studies | + | === Studies also showed === |
Line 110: | Line 127: | ||
=== Long term treatment === | === Long term treatment === | ||
- | Data suggest 40 & 80 mg olmesartan | + | |
// | // | ||
{{tag> | {{tag> | ||